We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 835

Mistake in pharmaceutical patent wording a hard pill to swallow
  • The Commercial Bar Association of Victoria
  • Australia
  • September 4 2018

Pain is, well, a pain. One medication commonly used to relieve and manage pain and fever is paracetamol. Paracetamol is safe in low doses, but at high

Paxil Verdict Overturned on Appeal - Preemption Evidence Couldn’t Be Clearer
  • Dechert LLP
  • USA
  • August 28 2018

We haven’t talked about the district court decisions in Dolin v. GlaxoSmithKline LLC, because in our opinion there simply hasn’t been anything good to

Seventh Circuit Finds Preemption in Reversing Generic Paxil Verdict Against GSK, But Passes on Deciding Innovator Liability Issues
  • Drinker Biddle & Reath LLP
  • USA
  • August 23 2018

In a much-anticipated ruling on the appeal of a $3 million verdict against GlaxoSmithKline (GSK) in a wrongful death case involving the Paxil generic

Potential EU-UK competition law divergence post-Brexit highlighted by conflicting approaches of UK Competition Appeal Tribunal in recent pharma cases
  • Mayer Brown
  • United Kingdom, European Union
  • August 14 2018

The UK Competition Appeal Tribunal (the "CAT") has recently issued two judgments relating to anticompetitive practices in the pharmaceutical sector

Arrow declarations - not just a one hit wonder?
  • Boult Wade Tennant LLP
  • United Kingdom
  • July 9 2018

On 28 June, the UK Court of Appeal granted permission for GSK to pursue their claim for Arrow relief in the case of Glaxo Group Limited & Ors v

Amendments to the Poisons Standard: Changes to patient access for medicines containing codeine
  • Barry.Nilsson. Lawyers
  • Australia
  • March 27 2018

On 1 February 2018 the Poisons Standard February 2018 commenced, restricting access to medicines containing codeine. Australians now require a

Depression delayed: CMA’s paroxetine pay-for-delay case heads to Luxembourg
  • Bristows
  • United Kingdom, European Union
  • March 15 2018

On 8 March 2018, the Competition Appeal Tribunal (CAT) gave an initial judgment (see here) in the appeals brought by GlaxoSmithKline (GSK) and a

MHRA issues alert over recall of three batches of asthma inhalers
  • Penningtons Manches LLP
  • United Kingdom, Germany
  • February 22 2018

The Medicines & Healthcare products Regulatory Agency (MHRA), which regulates the safety of drugs and medical devices in the UK, has issued a drug

GSK responding to inquiries from SFO, DOJ, and SEC regarding its use of third party advisors in China
  • Buckley Sandler LLP
  • USA
  • February 9 2018

In a securities filing on Wednesday, Feb. 7, U.K.-based pharmaceutical company GlaxoSmithKline PLC (“GSK”) announced that it is responding to

Medicare Part D Cost Sharing Trends for Adult Vaccines
  • Manatt Phelps & Phillips LLP
  • USA
  • January 30 2018

Vaccination utilization among U.S. adults is low, and well below the Healthy People 2020 targets, despite widespread availability of safe and